Enhanced clinical decision-making improves targeted gene panel testing for inborn errors of immunity, indicating a need for better testing protocols.
Genetic testing for IEI should be strongly considered in patients with positive newborn SCID screen, clinical diagnoses of CID or SCID, and immune dysregulation with multiple autoimmunity, or non-atopic skin lesions.
No takes yet. Share an insight, caveat, or question.
Udomkittivorakul et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: